
-
After 100 days in office, Trump voters still back US president
-
US anti-disinformation guardrails fall in Trump's first 100 days
-
Dick Barnett, two-time NBA champ with Knicks, dies at 88
-
PSG hope to have Dembele firing for Arsenal Champions League showdown
-
Arteta faces Champions League showdown with mentor Luis Enrique
-
Niemann wins LIV Mexico City to secure US Open berth
-
Slot plots more Liverpool glory after Premier League triumph
-
Novak and Griffin win PGA pairs event for first tour titles
-
Inter Miami unbeaten MLS run ends after Dallas comeback
-
T'Wolves rally late to beat Lakers, Knicks edge Pistons amid controversy
-
Japan's Saigo wins playoff for LPGA Chevron title and first major win
-
Trump tells Putin to 'stop shooting' and make a deal
-
US says it struck 800 targets in Yemen, killed 100s of Huthis since March 15
-
Conflicts spur 'unprecedented' rise in military spending
-
Gouiri hat-trick guides Marseille back to second in Ligue 1
-
Racing 92 thump Stade Francais to push rivals closer to relegation
-
Inter downed by Roma, McTominay fires Napoli to top of Serie A
-
Usyk's unification bout against Dubois confirmed for July 19
-
Knicks edge Pistons for 3-1 NBA playoff series lead
-
Slot praises Klopp after Liverpool seal Premier League title
-
FA Cup glory won't salvage Man City's troubled season: Guardiola
-
Bumrah, Krunal Pandya star as Mumbai and Bengaluru win in IPL
-
Amorim says 'everything can change' as Liverpool equal Man Utd title record
-
Iran's Khamenei orders probe into port blast that killed 40
-
Salah revels in Liverpool's 'way better' title party
-
Arsenal stun Lyon to reach Women's Champions League final
-
Slot 'incredibly proud' as Liverpool celebrate record-equalling title
-
Israel strikes south Beirut, prompting Lebanese appeal to ceasefire guarantors
-
Smart Slot reaps rewards of quiet revolution at Liverpool
-
Krunal Pandya leads Bengaluru to top of IPL table
-
Can Trump-Zelensky Vatican talks bring Ukraine peace?
-
Van Dijk hails Liverpool's 'special' title triumph
-
Five games that won Liverpool the Premier League
-
'Sinners' tops N.America box office for second week
-
Imperious Liverpool smash Tottenham to win Premier League title
-
Man City sink Forest to reach third successive FA Cup final
-
Toll from Iran port blast hits 40 as fire blazes
-
Canada car attack suspect had mental health issues, 11 dead
-
Crowds flock to tomb of Pope Francis, as eyes turn to conclave
-
Inter downed by Roma, AC Milan bounce back with victory in Venice
-
Religious hate has no place in France, says Macron after Muslim killed in mosque
-
Last day of Canada election campaign jolted by Vancouver attack
-
Barcelona crush Chelsea to reach women's Champions League final
-
Nine killed as driver plows into Filipino festival in Canada
-
Germany marks liberation of Bergen-Belsen Nazi camp
-
Hojlund strikes at the death to rescue Man Utd in Bournemouth draw
-
Zelensky says Ukraine not kicked out of Russia's Kursk
-
Zverev, Sabalenka battle through in Madrid Open, Rublev defence over
-
Ruthless Pogacar wins Liege-Bastogne-Liege for third time
-
Bumrah claims 4-22 as Mumbai register five straight IPL wins

Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event
Immuron Limited (NASDAQ:IMRN) has one commercial product and two pipeline assets in three clinical programs for the treatment of gut mediated diseases. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.
Event: Q4 Investor Summit
Presentation Time: 10:30am - 11:00am ET
Location: https://www.webcaster4.com/Webcast/Page/3075/51674
The theme is 40 micro-cap companies with a catalyst and/or strong performance in the current market.
Take a deep dive with the best Investors in MicroCap
Live Q & A
Complimentary to Qualified Investors. Please REGISTER HERE.
About the Investor Summit
The Investor Summit is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. Founded in 2015.
Contact:
Fred Rockwell
[email protected]
Investor Summit Group
About Immuron
Immuron Limited (ASX:IMC, NASDAQ:IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.
About Travelan®
Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers' diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers' diarrhea. In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers' Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers' Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection.
Travelers' diarrhea (TD)
TD is generally defined as the passage of ≥ 3 unformed stools per 24 hours plus at least one additional symptom (such as nausea, vomiting, abdominal cramps, fever, blood/mucus in the stools, or fecal urgency) that develop while abroad or within 10 days of returning from any resource-limited destinations (Leung et al., 2006). Diarrhea continues to be the most frequent health problem among travelers to destinations in lower- and middle-income regions (Steffen, 2017). Deployed US military personnel, essentially representing a long-term traveller population, are particularly affected given their population dynamics and the context in which they seek care and treatment (Connor et al., 2012). Diarrhea is the leading infectious disease threat to the overall health and preparedness of deployed US armed forces, with diarrheagenic E. coli, Campylobacter spp., and Shigella spp. among the most commonly reported etiologies (Riddle et al., 2006).
Immuron Platform Technology
Immuron's proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits directly to the bacteria found there. The underlying nature of Immuron's platform technology enables the development of medicines across a large range of infectious diseases. The platform can be used to block viruses or bacteria at mucosal surfaces such as the Gastrointestinal tract and neutralize the toxins they produce.
IMM-124E (Travelan®)
IMM-124E was developed using Immuron's platform technology. IMM-124E is produced from the colostrum of birthing cattle that have been immunised during pregnancy with a vaccine containing the outer antigens of multiple human derived ETEC. A total of 13 ETEC strains are used in the vaccine to produce high levels of antibodies against selected surface antigens from the most common strains of ETEC.
The resultant hyperimmune colostrum IMM-124E from ETEC vaccinated cows contains significant levels of polyclonal antibodies specific for ETEC antigens LPS, CFA-I and Flagellin (Sears et al., 2017).
The antibodies produced in IMM-124E have been found to have a stronger binding and neutralizing activity (than the antibodies of unvaccinated cattle) against a wide range of LPS antigens including both the variable O-polysaccharide region and the preserved oligosaccharide core 'R' region of LPS from the 13 serotypes used in the ETEC vaccine.
IMM-124E is manufactured into a tablet form referred to as Travelan®.
IMM-529
Immuron is developing IMM-529 as an adjunctive therapy in combination with standard of care antibiotics for the prevention and/or treatment of recurrent Clostridioides difficile infection (CDI). IMM-529 antibodies targeting Clostridioides difficile (C. diff) may help to clear CDI infection and promote a quicker re-establishment of normal gut flora, providing an attractive oral preventative for recurrent CDI.
Immuron is collaborating with Dr. Dena Lyras and her team at Monash University, Australia to develop vaccines to produce bovine colostrum-derived antibodies. Dairy cows were immunised to generate hyperimmune bovine colostrum (HBC) that contains antibodies targeting three essential C. diff virulence components. IMM-529 targets Toxin B (TcB), the spores and the surface layer proteins of the vegetative cells.
This unique 3-target approach has yielded promising results in pre-clinical infection and relapse models, including (1) Prevention of primary disease (80% P =0.0052); (2) Protection of disease recurrence (67%, P
To our knowledge, IMM-529 is, to date, the only investigational drug that has shown therapeutic potential in all three phases of the disease (Hutton et al., 2017).
References
Connor P, Porter CK, Swierczewski B and Riddle MS. Diarrhea during military deployment: current concepts and future directions. Curr Opin Infect Dis. 25(5): 546-54; 2012.
Hutton, M.L., Cunningham, B.A., Mackin, K.E. et al. Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative. Sci Rep 7, 3665 (2017). https://doi.org/10.1038/s41598-017-03982-5
Leung AK, Robson WL, Davies HD. Travelers' diarrhea. Adv Ther. Jul-Aug; 23(4): 519-27; 2006
Otto W, Najnigier B, Stelmasiak T and Robins-Browne RM. Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea caused by enterotoxigenic Escherichia coli in volunteers Scandinavian Journal of Gastroenterology 46: 862- 868; 2011.
Riddle MS, Sanders JW, Putnam SD, and Tribble DR. Incidence, etiology, and impact of diarrhea among long-term travelers' (US military and similar populations): A systematic review. American Journal of Tropical Medicine and Hygiene. 74(5): 891-900; 2006.
Sears KT, Tennant SM, Reymann MK, Simon R, Konstantopolos N, Blackwelder WC, Barry EM and Pasetti MF. Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic Escherichia coli Hyperimmune Bovine Colostrum products. Clinical and Vaccine Immunology. 24 (8) 1-14; 2017.
Steffen R. Epidemiology of travelers' diarrhea. J Travel Med. 24(suppl_1): S2-S5; 2017.
For more information visit: https://www.immuron.com.au/ and https://www.travelan.com
FORWARD-LOOKING STATEMENTS:
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.
SOURCE: Immuron Limited
A.Rodriguezv--AMWN